This firm's breakthrough has drawn investments from the biggest names in Big Pharma - With companies like Biogen, Sanofi, and Genentech pouring over $1 billion into it.

Unlock the details of this groundbreaking opportunity here...

Philip A. Downing net worth and biography

Philip Downing Biography and Net Worth

VP of Inotiv

Philip Downing brings to Inotiv over 22 years of pharmaceutical experience in drug discovery, toxicology/non-clinical, and clinical research to his role as senior vice president of nonclinical services. Trained as a bioanalytical chemist, Downing joined Inotiv’s legacy company, BASi, as an analytical chemist in 1997, rapidly progressing through leadership positions of increasing responsibility as director of analytical services, general manager, and senior director of preclinical services, before taking on his current executive role.

Previously, Downing worked at GFi Pharmaceuticals (now the clinical division within Covance Labs) as an analytical scientist and radiation safety officer designing and validating radiolabeled and non-radiolabeled assays used to support clinical ADME studies. He is a member of the Society of Toxicology, the American College of Toxicology, and the American Chemical Society.

BACK TO TEAM

What is Philip A. Downing's net worth?: The estimated net worth of Philip A. Downing is at least $109,501.25 as of June 10th, 2019. Mr. Downing owns 25,765 shares of Inotiv stock worth more than $109,501 as of April 25th. This net worth estimate does not reflect any other investments that Mr. Downing may own. Learn More about Philip A. Downing's net worth.
How do I contact Philip A. Downing?: The corporate mailing address for Mr. Downing and other Inotiv executives is 2701 KENT AVENUE, WEST LAFAYETTE IN, 47906. Inotiv can also be reached via phone at (765) 463-4527 and via email at [email protected]. Learn More on Philip A. Downing's contact information.
Has Philip A. Downing been buying or selling shares of Inotiv?: Philip A. Downing has not been actively trading shares of Inotiv over the course of the past ninety days. Most recently, on Tuesday, February 22nd, Philip A. Downing bought 2,000 shares of Inotiv stock. The stock was acquired at an average cost of $23.97 per share, with a total value of $47,940.00. Learn More on Philip A. Downing's trading history.
Who are Inotiv's active insiders?: Inotiv's insider roster includes Philip Downing (VP), and John Sagartz (Insider). Learn More on Inotiv's active insiders.
Are insiders buying or selling shares of Inotiv?: During the last year, Inotiv insiders bought shares 2 times. They purchased a total of 52,966 shares worth more than $163,803.92. The most recent insider tranaction occured on December, 14th when insider Michael Garrett bought 5,000 shares worth more than $14,150.00. Insiders at Inotiv own 5.8% of the company. Learn More about insider trades at Inotiv.
Information on this page was last updated on 12/14/2023.

Philip A. Downing Insider Trading History at Inotiv

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/22/2022	Buy	2,000	$23.97	$47,940.00
12/22/2021	Sell	3,057	$43.04	$131,573.28

Philip A. Downing Buying and Selling Activity at Inotiv

Inotiv Company Overview

Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company offers research and discovery services, including computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services, as well as model and research services. The company operates in the United States, the Netherlands, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.

Today's Range

Now: $4.29

$4.11

$4.59

50 Day Range

MA: $7.53

$4.29

$11.04

2 Week Range

Now: $4.29

$1.61

$11.42

Volume

523,271 shs

Average Volume

421,107 shs

Market Capitalization

$110.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.16

Jim Cramer’s “The Biggest Drug Ever”

From Behind the Markets | Ad